Innate Pharma S.A. (IPHA)

Innate Pharma Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-7.57	-58.1	-52.81	-63.98	-20.76
Depreciation & Amortization	5.09	45.41	4.6	56.8	16.53
Share-Based Compensation	4.26	4.25	2.62	2.48	3.83
Other Operating Activities	-34.34	-10.71	-12.86	-47.06	35.33
Operating Cash Flow	-32.56	-19.16	-58.46	-51.77	34.92
Capital Expenditures	-0.2	-0.54	-0.92	-0.9	-1.27
Acquisitions	-0	-0	-0	-0.06	-0.01
Change in Investments	22.77	3	0.37	-2.04	3.29
Other Investing Activities	-1.93	-0.59	-0.36	-10.38	-64.13
Investing Cash Flow	20.63	1.88	-0.92	-13.37	-62.12
Share Issuance / Repurchase	0.4	0.2	0.5	0.05	66.05
Debt Issued / Paid	-2.36	-2.03	26.63	-0.89	11.92
Other Financing Activities	-	-	-0.31	-0.34	-0.2
Financing Cash Flow	-1.97	-1.83	26.82	-1.18	77.77
Net Cash Flow	-13.62	-19.53	-33.04	-66.1	50.57
Free Cash Flow	-32.76	-19.69	-59.38	-52.67	33.65
Free Cash Flow Margin	-53.14%	-34.14%	-240.37%	-75.48%	39.38%
Free Cash Flow Per Share	-0.41	-0.25	-0.75	-0.67	0.45

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).